Evidence shows the Alzheimer’s disease (AD) process begins a decade or more before the onset of symptoms.
By identifying patients at risk for the disease, DOs have the opportunity to assess their cardiovascular health and counsel them on risk modification strategies they can employ before the illness is diagnosed.
An Update on Alzheimer’s Disease for the Primary Care Clinician: Initiating the Dialogue Earlier reviews the latest insights into the pathophysiology and treatments under development to intervene early in the disease cascade. The CME course is approved for 1.5 AOA Category 1-B CME credits. Topics covered include initiating the dialogue with patients at risk for AD, referring patients early, evaluating the role of imaging, assessing cardiovascular health, and enrollment in clinical trials and registries.
“Alzheimer’s disease is the sixth leading cause of death in America. Contrary to what many patients believe, there are steps they can take to help themselves. The earlier the diagnosis is made, the more benefit is likely to be seen,” said Eric McDade, DO, assistant professor of neurology at Washington University School of Medicine in St. Louis.
Dr. McDade and Marwan Noel Sabbagh, MD, director of the Alzheimer’s Disease and Memory Disorders Division at Barrow Neurological Institute, detail the latest evidence-based recommendations and intervention strategies in the online course.
Upon completion of this activity, participants will be better able to:
• Describe the neurobiology of AD and the need to intervene early in the disease cascade
• Describe the role of biomarkers in AD diagnosis
• Summarize treatments for AD in late-stage development
• Communicate with patients at risk for AD and provide information about risk modification strategies, clinical trials and registries
Enroll in the course here.